WO2004100989A1 - いびき又は睡眠時の呼吸障害の予防・治療剤 - Google Patents
いびき又は睡眠時の呼吸障害の予防・治療剤 Download PDFInfo
- Publication number
- WO2004100989A1 WO2004100989A1 PCT/JP2004/007106 JP2004007106W WO2004100989A1 WO 2004100989 A1 WO2004100989 A1 WO 2004100989A1 JP 2004007106 W JP2004007106 W JP 2004007106W WO 2004100989 A1 WO2004100989 A1 WO 2004100989A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycine
- snoring
- during sleep
- sleep
- apnea
- Prior art date
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 156
- 206010041235 Snoring Diseases 0.000 title claims abstract description 143
- 230000003449 preventive effect Effects 0.000 title claims abstract description 17
- 230000000241 respiratory effect Effects 0.000 title abstract description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 345
- 239000004471 Glycine Substances 0.000 claims abstract description 171
- 150000001875 compounds Chemical class 0.000 claims abstract description 56
- 235000013305 food Nutrition 0.000 claims abstract description 52
- 102000011714 Glycine Receptors Human genes 0.000 claims abstract description 18
- 108010076533 Glycine Receptors Proteins 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 238000001727 in vivo Methods 0.000 claims abstract description 7
- 230000008484 agonism Effects 0.000 claims abstract 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 97
- 239000003814 drug Substances 0.000 claims description 49
- 208000008784 apnea Diseases 0.000 claims description 48
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 44
- 229940124597 therapeutic agent Drugs 0.000 claims description 41
- 206010021079 Hypopnoea Diseases 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 35
- 230000002265 prevention Effects 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 201000002859 sleep apnea Diseases 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 24
- 239000000470 constituent Substances 0.000 claims description 23
- 230000000069 prophylactic effect Effects 0.000 claims description 21
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- 239000000556 agonist Substances 0.000 claims description 14
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 13
- 230000000414 obstructive effect Effects 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 11
- 208000006673 asthma Diseases 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 239000013589 supplement Substances 0.000 claims description 7
- 208000003417 Central Sleep Apnea Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 230000001270 agonistic effect Effects 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 238000011156 evaluation Methods 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 19
- 230000035622 drinking Effects 0.000 description 19
- 239000001301 oxygen Substances 0.000 description 19
- 229910052760 oxygen Inorganic materials 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000002431 glycine receptor agonist Substances 0.000 description 12
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 11
- 230000008452 non REM sleep Effects 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- -1 D-aranan Chemical compound 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229940122391 Glycine receptor agonist Drugs 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 208000019116 sleep disease Diseases 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 229960003067 cystine Drugs 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010000117 Abnormal behaviour Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 239000004158 L-cystine Substances 0.000 description 3
- 235000019393 L-cystine Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000032140 Sleepiness Diseases 0.000 description 3
- 206010042434 Sudden death Diseases 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010027951 Mood swings Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 108010013296 Sericins Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 229940127337 Glycine Antagonists Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000023668 Pharyngeal disease Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010068956 Respiratory tract inflammation Diseases 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- OBESRABRARNZJB-UHFFFAOYSA-N aminomethanesulfonic acid Chemical compound NCS(O)(=O)=O OBESRABRARNZJB-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000033420 disorder of pharynx Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004335 respiratory allergy Diseases 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an agent for preventing or treating snoring or respiratory disorders during sleep, and a food and feed effective for preventing or relieving respiratory disorders during snoring or sleeping.
- Snoring occurs when the airway mucous membranes, such as the pharynx, vibrate as the airway does not become narrowed or obstructed due to reduced pharyngeal or tongue muscle tone during sleep.
- causes include obesity, drinking alcohol, taking sleeping pills, aging, nasal diseases such as adenoids, and pharyngeal disorders.
- Snoring not only interferes with the sleep of a cohabitant, that is, not only causes annoyance to others, but also impairs sound sleep, and leads to sleepiness, concentration, vitality, decreased memory, and mental instability during Preventing snoring is important for providing good sleep for the cohabitants and for themselves, increasing vitality during the day and maintaining good health.
- the causes of sleep apnea include those caused by abnormalities of the respiratory center in addition to the airway obstruction described above.
- Snoring and sleep apnea not only interfere with daytime activities, but may also cause traffic accidents due to drowsiness, and temporary cessation of breathing, resulting in a lack of oxygen in the body, which may cause damage to the circulatory and central systems. It is known to affect and cause various obstacles. For example, it has been linked to hypertension, cerebral infarction, ischemic heart disease, arrhythmia, and sudden death, and is regarded as a disease requiring prevention and treatment. If the treatment of snoring or sleep apnea is considered to involve obesity, alcohol drinking, sleeping pills, analgesics, psychotropic stabilizers, etc. Review of lifestyle, etc. is the first treatment and And prevention.
- Drug-based treatment such as snoring due to respiratory tract inflammation or allergies, and sleep apnea, drugs such as steroids may be effective.
- antihypertensive diuretics acetazolamide
- the outcome is not always satisfactory.
- drugs that inhibit the activity of central glutamate-euron i.e., inhibitors of glutamate or glycine receptors, or daltamate or glycine It has been reported that antagonists may be effective in the treatment of sleep apnea (WO No. 519,590, pan fret), and glutamin was determined in animal experiments using rats. The effectiveness of riluzole, an acid antagonist, has been confirmed. However, glutamate-glycine antagonists having such medicinal effects have not yet been used in clinical settings, and their efficacy in humans has not been confirmed.
- the problem to be solved by the present invention is a drug for preventing or reducing snoring and preventing or treating respiratory disorders during sleep, and a food and feed for preventing or alleviating snoring or respiratory disorders during sleep.
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, it has been found that the occurrence of snoring is suppressed by taking glycine, and furthermore, sleep apnea is suppressed, and sleep apnea is suppressed. Inhibition of arterial oxygen saturation (SpO 2 ) reduction due to ozone was found.
- the effect is metabolized via glycine in the body, It can also be achieved by serine that increases the amount of glycine in the body, or a peptide or protein containing glycine and / or serine at a high ratio as a constituent amino acid. That is, any compound that can exist as glycine in a living body can exert the above-mentioned action.
- the action can also be achieved by a compound having an agonist action on a glycine receptor (hereinafter, also referred to as “glycine receptor agonist”).
- glycine etc. compounds that can exist as glycine in the living body (hereinafter referred to as “glycine etc.”) and glycine receptor agonists have been used to prevent snoring and respiratory disorders during sleep ′
- the present invention was completed after confirming that it can be used for treatment or that glycine and the like and glycine receptor agonist can be used for the manufacture of a therapeutic agent for preventing snoring and respiratory disorders during sleep.
- Glycine and the like and glycine receptor agonists can be used by adding to food or feed for the purpose of preventing snoring and respiratory disorders during sleep.
- the present invention is as follows.
- a prophylactic / therapeutic agent for snoring or respiratory disorders during sleep comprising a compound having an agonist action on daricin receptor as an active ingredient.
- a prophylactic / therapeutic agent for snoring or respiratory disorders during sleep which comprises a compound present as glycine in the living body as an active ingredient.
- a compound which may exist as glycine in a living body is a peptide containing glycine, serine, daricin and / or serine as a constituent amino acid, and glycine and / or sericin.
- the preventive or therapeutic agent for snoring or respiratory disorder during sleep according to the above (2) which is selected from proteins containing amino acids as constituent amino acids.
- hypopnea or apnea during sleep is obstructive hypopnea or obstructive apnea, or central hypopnea or central apnea. Or prevention of breathing disorders during sleep.
- a food for preventing / alleviating snoring or respiratory disorders during sleep which contains a compound having an agonist effect on glycine receptors.
- a feed for preventing or alleviating snoring or respiratory disorders during sleep which contains a compound having an agonist effect on glycine receptors.
- Snoring or respiratory disorders during sleep including ingesting feed containing a compound that may exist as glycine in the body to animals that need to prevent or alleviate respiratory disorders during snoring or sleep Prevention and mitigation methods.
- Compounds that can be present as glycine in the living body include glycine, serine, glycine and a peptide containing glycine and / or serine as a constituent amino acid, and daricin and / or serine. (33) The use according to the above (33), which is selected from proteins contained as constituent amino acids.
- hypopnea or apnea during sleep is obstructive hypopnea or obstructive apnea
- hypopnea or apnea during sleep is obstructive hypopnea or obstructive apnea
- the use according to (35) above, which is central hypopnea or central apnea is central hypopnea or central apnea.
- the amount of intake or dosage is 0.06-250 mg Z kg / day in terms of the free form of glycine, or the release of serine (33) or (34) above for snoring at a body conversion of 0.1 to 400 mg / kg / day -or for the manufacture of a remedy for preventing or treating respiratory disorders during sleep Use as described in.
- Figure 1 is a transition of a typical apnea observed in 6 minutes oronasal breathing pattern (top) and arterial oxygen saturation measured simultaneously (S P 0 2,% saturation) (bottom) FIG.
- the temperature rise due to exhalation and the temperature decrease due to inhalation of the temperature sensor attached to the mouth and nose are shown as a mouth-nose breathing pattern. Shadow represents apnea (top) and S P 0 2 drops (lower). S P 0 2 drop is observed after the occurrence of apnea.
- Figure 2 is a diagram showing a Sp0 2 transition in control without changes (bottom) and taking arterial oxygen saturation I from falling asleep to waking up when taking glycine tablets (Sp0 2,% saturation) (top). Bars represent 80 minutes.
- Fig. 3 shows typical examples of tracheal sounds (snoring sound) when taking a glycine tablet (bottom) and tracheal sounds in a non-taking control (top).
- the amplitude represents the volume of the tracheal sound. Bars represent 5 minutes-.
- FIG. 4 is a graph showing the results of measurement of AHI during sleep after taking glycine and after taking placebo in Example 2.
- Figure 4 Left graph shows AHI after taking glycine in the total sleep period, REM sleep period and non-REM sleep period (Total), REM sleep period (REM), and non-REM sleep period (NREM). The average value (black bar graph) and the average value of AHI after taking placebo (open bar graph) are shown.
- Fig. 4 Right graph shows the average value of AHI after taking glycine (black bar graph) and the average value of AHI after taking placebo (open bar graph) in Total, REM, and NREM at the beginning of sleep (3 hours). Is shown.
- FIG. 5 is a graph showing the results of measuring AHI during sleep after taking glycine and taking placebo in Example 2, and the left graph of FIG. 5 shows glycine intake in subjects aged 40 and over.
- the average values of AHI after treatment (black bar Daraf) and the average values of AHI after taking placebo (open bar graph) are shown.
- the average value of AHI after taking Shin (black bar graph) and the average value of AHI after taking placebo (open bar graph) are shown.
- * indicates significance.
- Prophylaxis of the invention 'therapeutic agent' Applies to snoring or respiratory disorders during sleep, such as snoring, obstructive or central hypopnea and apnea seen in so-called sleep apnea syndrome, and other causes such as asthma Examples include hypopnea and apnea caused by the disease.
- a glycine receptor agonist is a substance that binds to a glycine receptor and exerts the same or similar action as that of glycine.
- glycine receptor agonists include, for example, aminomethansulfonic acid, D-aranan, L-alanine, ⁇ -alanin, taurine, hypotaurine, dodecine G, dusilin G, Chlormethia azole, and Ivermectin (I vermec tin).
- the compound that can be present as glycine in the living body includes not only glycine, but also, for example, a compound that forms glycine by cleavage of a peptide bond, such as a protein, after administration, or Also includes compounds that produce glycine in vivo, such as compounds that produce glycine by metabolism such as serine (may be compounds that produce glycine during metabolism). It is a concept.
- Examples of the compound that can exist as dalicine in a living body include, for example, glycine, serine, a peptide containing glycine and / or serine as a constituent amino acid in a high ratio, glycine and / or sericin And proteins containing a high proportion of amino acids as constituent amino acids.
- Serine is metabolized via glycine in the body, resulting in an increase in the amount of glycine in the body.
- Peptides containing glycine and / or serine as constituent amino acids, and proteins containing darisin and nose or serine as constituent amino acids are decomposed into glycine and serine by digestion and the like, and glycine in the body. Increase the amount.
- the peptide containing glycine and / or serine as a constituent amino acid is preferably contained as much as glycine and serine as a constituent amino acid.
- Peptides whose serine content is the total amount of glycine and serine are ⁇ .i to igZg peptides, preferably 0.3 to 1 g / g peptide.
- the protein containing glycine and / or serine as a constituent amino acid should preferably contain a large amount of daricin and serine as a constituent amino acid.For example, the content of glycine and serine should be high.
- peptide or protein containing daricin and / or serine as a constituent amino acid include silk, collagen, gelatin, and peptides obtained by chemical synthesis.
- No. -Glycine and the like and the glycine receptor agonist may be in the form of a salt.
- glycine "serine”, “amino acid constituting glycine and / or serine” is used.
- the term ”) is a concept that includes salts.
- the salt is not particularly limited as long as it is pharmacologically acceptable, and examples thereof include salts with an inorganic acid or an organic acid.
- Salts with inorganic acids include, for example, salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like.
- Salts with organic acids include, for example, formic acid, acetic acid, Examples thereof include salts with trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, oxalic acid, fumaric acid, maleic acid, citric acid, malonic acid, methanesulfonic acid and the like.
- It can also be a salt with a base.
- the salt with a base include alkali metal salts such as sodium salts and potassium salts, and alkaline earth metal salts such as calcium salts and magnesium salts.
- the prophylactic / therapeutic agent of the present invention is administered in the form of a known pharmaceutical preparation or a pharmaceutical preparation to be developed in the future, for example, oral or parenteral administration.
- Oral administration is simple and preferred.
- Oral dosage forms include powders, granules, tablets, Examples include solid preparations such as capsules, solution preparations such as syrup and juice, milk preparations and suspension preparations.
- parenteral administration preparations include injection, enteral, transdermal, and inhalation preparations. These preparations can be immediate- or delayed-release (sustained-release) preparations.
- an appropriate pharmaceutically acceptable carrier for example, a usual preparation substance can be used as an auxiliary, depending on the dosage form of each preparation.
- Pharmaceutical substances include, for example, excipients, diluents, additives, disintegrants, binders, coatings, lubricants, glidants, lubricants, flavors, sweeteners, solubilizers, etc. Can be mentioned.
- substances for preparation include magnesium carbonate, titanium dioxide, lactose, mannitol, dextrin and other sugars, talc, milk protein, gelatin, starch, cellulose (crystalline cellulose) and Derivatives, animal and vegetable oils, polyethylene glycols, glycerin fatty acid esters, finely divided silicon dioxide, solvents such as sterile water and polyhydric alcohols (such as ethanol) or polyhydric alcohols (such as glycerol), penila Flavors and the like are exemplified.
- the content of the active ingredient of the glycine receptor agonist, such as glycine, in the prophylactic / therapeutic agent of the present invention in the above-exemplified preparation form is not particularly limited, and contains the amount necessary for exerting the drug effect. It may be appropriately prepared so that
- the prophylactic / therapeutic agent of the present invention can be made into a commercial package which is packaged together with a description describing the use of the prophylactic / therapeutic agent.
- Ingestion or administration is intended for humans and animals (including experimental animals).
- the amount of glycine and the like to be ingested or dosed is about 0.06 to 250 mg / kg in terms of the free form of glycine, more preferably about 0.25 to 625 mg / kg per day. / day, more preferably about 1.25 to 125 mg Z kg Z day. Or about 0.1 to 400 mg / kg / day, more preferably 0.4 to 240 mg / kg / da It is about y, and more preferably about 1.6 to 600 mg / kg / day.
- the glycine receptor agonist intake or dosage varies depending on the type of drug, but is preferably from 0.001 to 600 mg / kg / day.
- these daily doses are orally or parenterally administered once or divided into 2 to 4 times at appropriate intervals. In the case of a single dose, it is preferable to take it before going to bed.
- sleep disorders due to snoring or hypopnea or apnea during sleep can be prevented, and pain of insomnia can be alleviated.
- sleep disorders due to snoring or hypopnea during sleep or apnea are prevented, somnolence during the day, distraction, memory loss, and Prevents abnormal behaviors, accidents, illness, short temper, waking up headache, mood swings, decreased libido, hallucinations and hearing loss, and other abnormal behaviors at night caused by sleep disorders, and caused by these sleep disorders Yes
- Social maladjustment due to various symptoms ⁇ Anxiety ⁇ Depression can be prevented.
- cerebrovascular disorders hypertension, polycythemia, pulmonary hypertension, pulmonary heart, congestive heart failure, ischemic heart disease which are complications of sleep apnea It can prevent the onset of arrhythmia, respiratory failure, sudden death, diabetes, obesity, cognitive impairment, mental disorders and dementia.
- the prophylactic / therapeutic agent of the present invention is effective in improving snoring and respiratory disorders (especially hypopnea apnea) during the entire sleep period from the onset of sleep to wakefulness, and is particularly effective at the beginning of sleep. .
- the prophylactic / therapeutic agent of the present invention is useful for those who are 40 years old or older, especially those who are 40 years old or older and who are obese (for example, obesity with a BMI of more than 28), snoring, sleep disordered breathing (particularly It has the effect of significantly improving apnea.
- the term “food” in the present invention means food in general (including beverages), and is regulated by the Ministry of Health, Labor and Welfare's functional food system in addition to general foods including so-called health foods. This includes foods for specified health uses and nutritionally functional foods, and also includes sub-divisions.
- glycine receptor agonists such as glycine
- general foods such as various processed foods and beverages, specified health foods, and nutritional products. It can be added to health functional foods such as functional foods or feed, or used as a supplement.
- the food according to the present invention is produced by a method known per se using a carrier acceptable as an appropriate food, for example, various processing ingredients, seasonings, flavors, sweeteners, and the like, and powders, tablets, Preparations such as capsules and drinks can be made.
- Carriers that are acceptable as foods include the pharmaceutically acceptable carriers described above.
- additives for nutritional supplementation such as vitamins, can be further blended.
- the feed in the present invention can be produced by a method known per se using a carrier acceptable as an appropriate feed, for example, ordinary feed materials.
- Carriers acceptable as feed include the aforementioned pharmaceutically acceptable carriers.
- the administration to animals can be carried out in the same manner as the administration to humans described above, or by adding to normal feed.
- the amount of glycine receptor agonist such as glycine contained in the food of the present invention is not particularly limited, but the daily intake is within the same range as the above-mentioned dose in the preventive / therapeutic agent of the present invention. I prefer to do it.
- Glycine tablets and tablets containing L-cystine as an amino acid other than glycine were taken before going to bed, and the snoring of the subjects while sleeping was evaluated by the family. Also, sleep apnea and arterial oxygen saturation Wado a (Sp0 2) were evaluated using Fukuda Denshi Co., Ltd. Sleep Tester LT-200.
- the subject was a 38-year-old healthy male (weight 82 kg, height 170 cra, body mass index (BMI) 28.3), and frequent apnea during bedtime has been observed by family members. Subjects do not receive any permanent medications and do not have the habit of taking nutritional supplements or nutritional supplements.
- a mixture of 2,625 g of L-cystine, 1,050 g of L-theanine, 1,710 g of dextrin, and 15 g of aspartame was added, and 1,500 g of crystalline cellulose and 70% ethanol (30% by weight) were added. They were kneaded and extruded and granulated. The obtained granulated product was dried to a moisture content of 1.6% or less and sized to obtain 16 mesh PASS particles, 37.5 g of fine silicon dioxide, 487.5 g of glycerin fatty acid ester and 75 g of Yura flavor Was added and mixed.
- the resulting mixture was tableted under the following conditions: 11 ⁇ , 500 mg, tableting pressure 2.0 ton, rotation speed 20 rpm, and hardness average 10 kg.
- a control tablet (diameter 11 ⁇ ) containing 175 mg of L-cystine and 70 mg of L-theun per tablet (cystine / theanine tablet) was manufactured.
- the arterial blood oxygen saturation during sleep (s P o 2 ) and nasal airflow were measured using a sleep tester LT-200 manufactured by Fukuda Electronics Co., Ltd.
- Arterial oxygen saturation (S P 0 2) a case where lowering of the left second finger tip to the sensor was measured by mounting arterial oxygen saturation to 93% or less (Sp0 2) persisted for more than 10 seconds S P 0 to 2 drops, S P 0 2 drop number per hour ⁇ Pi per day, and to determine the minimum Sp0 2 daily.
- Mouth-nose airflow was measured by the thermocouple method, and a hypopnea was defined as a state in which the mouth-nose flow decreased to 50% or less for 10 seconds or more.
- the dose increased up to 4 out of 9 (frequency 44%) with 2 tablets and 6 out of 8 days (frequency 75%) with 4 tablets. Since drinking is known to promote snoring, the number of days of drinking was shown when glycine was not taken, when 2 tablets were taken, and when 4 tablets were taken (Table 1). Glycine tablets were consumed more frequently when 2 or 4 glycine tablets were taken, indicating that snoring was not suppressed due to abstinence from drinking, and it was clear that taking glycine tablets suppressed snoring. It is.
- Glycine tablets were taken 0 to 4 tablets before bedtime, and the following morning, a family member evaluated the presence or absence of snoring.
- the snoring evaluation results showed the number of days in which no snoring was observed (evaluation minus (one)), moderate (evaluation plus (+)), and severe (evaluation two plus (+ +)) snoring .
- the percentage of the total number of observation days for each of the days with a rating of 1, +, ++ is shown.
- the number of days of drinking in parentheses, the percentage of total observation days) is shown.
- Example 2 We examined whether the control tablet had the same snoring suppression effect as the glycine tablet. After an observation period (5 days) in which none of the tablets were taken, 4 control tablets were taken every 10 days before going to bed, and the presence of snoring was observed for 50 days without taking the reconstituted tablets. After that, four glycine tablets (containing 980 rag of glycine) were taken before bedtime and observed for snoring for 9 days.
- Control tablet 10 B 2 says 4 says 7
- a family member assessed the presence or absence of snoring. Snoring is observed in the snoring evaluation results
- tracheal sounds were simultaneously monitored.
- a typical example is shown in Fig. 3.
- the tracheal sound when taking glycine tablets tended to be suppressed compared to the control group when not taking glycine tablets.
- a decrease in arterial oxygen saturation due to sleep apnea also stimulates arousal, resulting in pathological sleep disorders. Further, it is said that this decrease in arterial oxygen saturation also contributes to circulatory diseases and the like.
- the present example demonstrated that glycine suppresses the occurrence of snoring and alleviates sleep apnea, and furthermore significantly suppresses the decrease in arterial oxygen saturation during sleep.
- a double-blind crossover test was conducted to confirm the effects of glycine on sleep disordered breathing. Sleep apnea with an AHI (Apnea hypopnea index per hour) below 5 The test was performed on 10 male adults with sclerosis. Glycine was taken 3 g one hour before going to bed, and placebo was used reduced maltose adjusted so as not to distinguish the taste.
- hypopnea and apnea Polysomnographic data such as electroencephalogram, electromyogram and arterial oxygen saturation during sleep were measured using an Alice system manufactured by Respironics, Inc. of the United States. The airflow in the mouth and nose was measured, and a hypopnea was defined as a condition in which the condition was reduced to 50% or less and continued for more than 10 seconds until the condition was restored to 60% or more. If the arterial oxygen saturation decreased by 3% or more in association with hypopnea, the patient was considered apnea. The sum of the apnea rate and the hypopnea rate per hour was called the apnea hypopnea index (AHI) and used as an index of the severity of sleep disordered breathing.
- AHI apnea hypopnea index
- the respiratory status during sleep after taking glycine or placebo was measured by the above-mentioned polysomnography.
- the average value of AHI after taking glycine was the entire period between REM sleep and non-REM sleep. ), REM sleep period (REM), and non-REM sleep period (NREM) showed lower values than the average value of AHI after taking placebo.
- the average AHI value after taking glycine vs. the average AHI value after taking placebo was the entire period of REM sleep period and non-REM sleep period, respectively.
- Total 13.4 vs. 15.0, REM sleep period (REM); 26.8 vs. 33.5, non-REM sleep period (NREM); 10.8 vs. 11.3. From the above results, it is clear that taking glycine improved sleep disordered breathing.
- hypopnea apnea was observed particularly frequently in the early stage of sleep (3 hours) after taking placebo, but taking glycine improved respiratory disorders in the early stages of sleep.
- glycine was effective in improving respiratory disorders during the entire sleep period, and was particularly effective in the early stages of sleep.
- glycine was shown to have a remarkable effect on respiratory disorders during sleep in those aged 40 or older, especially those aged 40 or older and who are obese (BMI> 2S).
- REM sleep is a condition in which the eyeballs move violently during sleep. It is known that REM sleep and non-REM sleep each have an important role in maintaining health.
- Example 2 As is clear from the results of Example 2 (Fig. 4), taking glycine during both the REM sleep period and the non-REM sleep period during the entire sleep period and the initial sleep period (3 hours). Improved respiratory disorders.
- the prophylactic and therapeutic agents of the present invention effectively prevent snoring and markedly suppress sleep apnea, so as to prevent and treat so-called sleep apnea syndrome, and to treat other diseases such as asthma. It is useful for the prevention and treatment of respiratory disorders caused by bleeding.
- Hypopnea with the preventive and therapeutic agents of the present invention ⁇ Good sleep is obtained by improving apnea, somnolence during sleep due to sleep disorders, distracted attention, poor memory, reduced work efficiency, accident Irritability, irritability, short temper, waking up, headache, mood swings, decreased libido, hallucinations and hearing loss, etc., and prevent abnormal behavior at night due to sleep disorders, and various symptoms caused by these sleep disorders Social maladjustment due to anxiety ⁇ Depression can be prevented.
- the consequences are prevention of daytime fatigue and increased vitality, reduced risk of serious accidents due to lack of concentration and falling asleep, and cerebrovascular disorders induced by sleep apnea.
- Hypertension, ischemic heart disease, arrhythmia, sudden death Etc. can be prevented from being induced.
- the preventive / therapeutic agent of the present invention Since the active ingredients glycine and the like and the glycine receptor agonist in the preventive / therapeutic agent of the present invention are substances with established safety, the preventive / therapeutic agent of the present invention has high safety. It can be used not only for pharmaceutical applications but also for food and feed.
- the present application is based on Japanese Patent Application No. 2003-141411, filed in Japan, the contents of which are incorporated in full herein.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020057022114A KR101081757B1 (ko) | 2003-05-19 | 2004-05-19 | 코골이 또는 수면시의 호흡 장애의 예방·치료제 |
EP04733953A EP1642589B8 (en) | 2003-05-19 | 2004-05-19 | Preventives/remedies for snore or respiratory disturbances during sleep |
JP2005506295A JP3948480B2 (ja) | 2003-05-19 | 2004-05-19 | いびき又は睡眠時の呼吸障害の予防・治療剤 |
US11/280,354 US20060128605A1 (en) | 2003-05-19 | 2005-11-17 | Preventives/remedies for snore or respiratory disturbances during sleep |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003141124 | 2003-05-19 | ||
JP2003-141124 | 2003-05-19 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/280,354 Continuation US20060128605A1 (en) | 2003-05-19 | 2005-11-17 | Preventives/remedies for snore or respiratory disturbances during sleep |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004100989A1 true WO2004100989A1 (ja) | 2004-11-25 |
Family
ID=33447430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/007106 WO2004100989A1 (ja) | 2003-05-19 | 2004-05-19 | いびき又は睡眠時の呼吸障害の予防・治療剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060128605A1 (ja) |
EP (1) | EP1642589B8 (ja) |
JP (1) | JP3948480B2 (ja) |
KR (1) | KR101081757B1 (ja) |
CN (1) | CN100488564C (ja) |
WO (1) | WO2004100989A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006333872A (ja) * | 2004-01-14 | 2006-12-14 | Ajinomoto Co Inc | グリシンを含有する食品及びその用途 |
US10561629B2 (en) | 2004-01-14 | 2020-02-18 | Ajinomoto Co., Inc. | Food containing glycine and use thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102316800A (zh) * | 2009-02-12 | 2012-01-11 | 俄勒冈健康科学大学 | 用于预防呼吸暂停的方法和装置 |
CN110325110B (zh) | 2016-11-10 | 2022-08-09 | 纽约州立大学研究基金会 | 用于气道阻塞的系统、方法和生物标记 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57193417A (en) * | 1981-05-23 | 1982-11-27 | Mochida Pharmaceut Co Ltd | Remedy for allergosis |
JPH05170647A (ja) * | 1991-02-15 | 1993-07-09 | Clintec Nutrition Co | 睡眠中の換気を改善する方法および睡眠に係る換気異常を処置する方法 |
WO2000051590A2 (en) * | 1999-03-04 | 2000-09-08 | The Board Of Trustees Of The University Of Illinois | Neuropharmacological treatment of sleep-related breathing disorders |
JP2002504510A (ja) * | 1998-02-27 | 2002-02-12 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 睡眠時無呼吸に対する処置のための、セロトニン関連活性を有する薬剤 |
WO2003015605A2 (en) * | 2001-08-20 | 2003-02-27 | University Of Virginia Patent Foundation | Use of s-nitrosothiol signaling to treat disordered control of breathing |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1059089C (zh) * | 1996-03-20 | 2000-12-06 | 吕勇 | 抗衰老保健药 |
JP4913410B2 (ja) * | 2004-01-14 | 2012-04-11 | 味の素株式会社 | グリシンを含有する食品およびその用途 |
-
2004
- 2004-05-19 KR KR1020057022114A patent/KR101081757B1/ko active IP Right Grant
- 2004-05-19 EP EP04733953A patent/EP1642589B8/en not_active Not-in-force
- 2004-05-19 CN CNB2004800138270A patent/CN100488564C/zh active Active
- 2004-05-19 JP JP2005506295A patent/JP3948480B2/ja not_active Expired - Fee Related
- 2004-05-19 WO PCT/JP2004/007106 patent/WO2004100989A1/ja active Application Filing
-
2005
- 2005-11-17 US US11/280,354 patent/US20060128605A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57193417A (en) * | 1981-05-23 | 1982-11-27 | Mochida Pharmaceut Co Ltd | Remedy for allergosis |
JPH05170647A (ja) * | 1991-02-15 | 1993-07-09 | Clintec Nutrition Co | 睡眠中の換気を改善する方法および睡眠に係る換気異常を処置する方法 |
JP2002504510A (ja) * | 1998-02-27 | 2002-02-12 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 睡眠時無呼吸に対する処置のための、セロトニン関連活性を有する薬剤 |
WO2000051590A2 (en) * | 1999-03-04 | 2000-09-08 | The Board Of Trustees Of The University Of Illinois | Neuropharmacological treatment of sleep-related breathing disorders |
WO2003015605A2 (en) * | 2001-08-20 | 2003-02-27 | University Of Virginia Patent Foundation | Use of s-nitrosothiol signaling to treat disordered control of breathing |
Non-Patent Citations (11)
Title |
---|
DUTSCHMANN M. ET AL: "Trigeminal reflex regulation of the glottis depends on central glycinergic inhibition in the rat", AM J PHYSIOL REGULATORY INTERGRATIVE COMP PHYSIOL, vol. 282, no. 4, 2002, pages R999 - R1005, XP002981833 * |
EGGERS E.D. ET AL: "Mechanisms for the modulation of native glycine receptor channels by ethanol", J. NEUROPHYSIOL, vol. 91, no. 6, June 2004 (2004-06-01), pages 2685 - 2695, XP002981827 * |
HORNER R.L.: "Is there a rationale in modulating brainstem neurons in obstructive sleep apnea and is it clinically relevant?", SLEEP, vol. 23, no. 4, 2000, pages S179 - S181, XP002981834 * |
INOUE: "Changes in tongue reflex responses during sleep", vol. 33, no. 1, 11 July 2003 (2003-07-11), pages 57 - 58, XP002981832 * |
KODAMA T. ET AL: "Changes in inhibitory amino acid release linked to pontine-induced atonia: An in vivo microdialysis study", J. NEUROSCI., vol. 23, no. 4, February 2003 (2003-02-01), pages 1548 - 1554, XP002981838 * |
KUBIN L. ET AL: "Suppression of Hypoglossal motoneurons during the carbachol-induced antonia of REM sleep is not caused by fast synaptic inhibition", BRAIN RES., vol. 611, no. 2, 1993, pages 300 - 312, XP000609478 * |
LAI Y-Y. ETAL: "Changes in monoamine release in the ventral horn and hypoglossal nucleus linked to pontine inhibiton of muscle tone: An in vivo microdialysis study", THE JOURNAL OF NEUROSCIENCE, vol. 21, no. 8, 2001, pages 7384 - 7391, XP002981839 * |
MORRISON J.L. ET AL: "Glycine at hypoglossal motor nucleus: genioglossus activity, CO2 responses, and the additive effects of GABA", J. APPL. PHYSIOL., vol. 93, no. 5, 2002, pages 1786 - 1796, XP002981836 * |
PATON J.F. ET AL: "Central control of upper airway resistance regulating respiratory airflow in mammals", J. ANAT., vol. 201, no. 4, 2002, pages 319 - 323, XP002981835 * |
SAARESRANTA T.: "Hormones and Breathing", CHEST JOURNAL, vol. 122, no. 6, 2002, pages 2165 - 2182, XP002981837 * |
YAMUY J. ET AL: "Hypoglossal Motoneurons are postsynaptically inhibited during carbachol-induced rapid eye movement sleep", NEUROSCIENCE, vol. 94, no. 1, 1999, pages 11 - 15, XP000922754 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006333872A (ja) * | 2004-01-14 | 2006-12-14 | Ajinomoto Co Inc | グリシンを含有する食品及びその用途 |
US10561629B2 (en) | 2004-01-14 | 2020-02-18 | Ajinomoto Co., Inc. | Food containing glycine and use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1642589B8 (en) | 2012-10-03 |
EP1642589B1 (en) | 2012-08-29 |
US20060128605A1 (en) | 2006-06-15 |
EP1642589A1 (en) | 2006-04-05 |
JP3948480B2 (ja) | 2007-07-25 |
CN1791428A (zh) | 2006-06-21 |
KR20060013410A (ko) | 2006-02-09 |
JPWO2004100989A1 (ja) | 2006-07-13 |
EP1642589A4 (en) | 2009-09-30 |
CN100488564C (zh) | 2009-05-20 |
KR101081757B1 (ko) | 2011-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3703831B2 (ja) | 中枢起原の睡眠無呼吸症及び呼吸疾患に対する効果を有する医薬の製造のためへのモダフィニルの使用 | |
US5140045A (en) | Method for improving ventilation during sleep and treating sleep related ventilation abnormalities of neonates | |
CA2555149C (en) | Method of treating and diagnosing sleep disordered breathing using zonisamide and means for carrying out the method | |
JP2009508854A (ja) | 睡眠時呼吸障害の予防及び治療方法及び手段 | |
JPH07324030A (ja) | 患者の睡眠質を改善する方法 | |
US20210338691A1 (en) | Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions | |
EP2964185B1 (en) | Preparations for the treatment of sleep-related respiratory disorders | |
Biering-Sørensen et al. | Sleep disordered breathing following spinal cord injury | |
US20060128605A1 (en) | Preventives/remedies for snore or respiratory disturbances during sleep | |
Tierney et al. | Obstructive sleep apnoea | |
US20170151222A1 (en) | Snoring treatment | |
Wieczorek et al. | Obstructive sleep apnea uncovered after high spinal anesthesia: a case report | |
IL261984A (en) | Sultiam for the treatment of sleep apnea | |
JP2006191933A (ja) | いびき又は睡眠時の呼吸障害の予防・治療剤 | |
KR20070010136A (ko) | 가복사돌을 이용한 손상된 호흡 기능의 치료 | |
WO2008047853A1 (fr) | Agent thérapeutique/prophylactique pour reflux gastro-oesophagien pathologique | |
Kirkness et al. | Pathogenesis of obstructive sleep apnea in obesity | |
WO2005011591A2 (en) | Method for the treatment of sleep disorders | |
Iaboni et al. | 11 Sleep and medical disorders | |
WO2000006163A1 (en) | Improved method for treatment of sleep-related respiratory disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005506295 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11280354 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057022114 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048138270 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004733953 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057022114 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004733953 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11280354 Country of ref document: US |